SEC Form 4 · accession 0001209191-19-013589
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Director
Period of report
Feb 22, 2019
Accepted (ET)
Feb 26, 2019 · 4:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 22, 2019 | M | 20,000 | $33.67 | A | 26,332 | D | |
| Common Stock | Feb 22, 2019 | M | 6,479 | $27.75 | A | 32,811 | D | |
| Common StockF1,F2 | Feb 22, 2019 | S | 11,479 | $82.1127 | D | 21,332 | D | |
| Common StockF1,F3 | Feb 22, 2019 | S | 14,490 | $81.7037 | D | 6,842 | D | |
| Common StockF1,F4 | Feb 22, 2019 | S | 510 | $82.2454 | D | 6,332 | D | |
| Common Stock | Feb 25, 2019 | M | 3,521 | $27.75 | A | 9,853 | D | |
| Common StockF1,F5 | Feb 25, 2019 | S | 3,000 | $78.8833 | D | 6,853 | D | |
| Common StockF1,F6 | Feb 25, 2019 | S | 521 | $79.8014 | D | 6,332 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F7 | $33.67 | Feb 22, 2019 | M | 20,000 | D | — | Sep 17, 2023 | Common Stock | 20,000 | 0 | D |
| Director Stock Option (right to buy) | $27.75 | Feb 22, 2019 | M | 6,479 | D | Jun 6, 2015 | Jun 6, 2024 | Common Stock | 6,479 | 3,521 | D |
| Director Stock Option (right to buy) | $27.75 | Feb 25, 2019 | M | 3,521 | D | Jun 6, 2015 | Jun 6, 2024 | Common Stock | 3,521 | 0 | D |
Explanation of responses
- F1Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F2Represents weighted average sale price. Actual sale prices ranged from $82.00 to $82.34.
- F3Represents weighted average sale price. Actual sale prices ranged from $81.21 to $82.20.
- F4Represents weighted average sale price. Actual sale prices ranged from $82.21 to $82.2538.
- F5Represents weighted average sale price. Actual sale prices ranged from $78.50 to $79.17.
- F6Represents weighted average sale price. Actual sale prices ranged from $79.54 to $80.02.
- F7The option became exercisable as to 25% of the shares on September 17, 2014, and became exercisable as to 1/48th of the shares each full month thereafter.